Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Literature DB >> 24047073

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Marco Gerlinger, Larry Norton, Charles Swanton.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2013 PMID： 24047073 DOI： 10.1056/NEJMc1309091

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

8 in total

1. Liquid biopsy: Potential and challenges.

Authors: Klaus Pantel; Catherine Alix-Panabières
Journal: Mol Oncol Date: 2016-02-01 Impact factor: 6.603

Review 2. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Authors: Min Yuan; Li-Li Huang; Jian-Hua Chen; Jie Wu; Qing Xu
Journal: Signal Transduct Target Ther Date: 2019-12-17

3. Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer.

Authors: Nicole M Kuderer; Kimberly A Burton; Sibel Blau; Francis Senecal; Vijayakrishna K Gadi; Stephanie Parker; Elisabeth Mahen; David Veenstra; Josh J Carlson; Gary H Lyman; C Anthony Blau
Journal: JCO Precis Oncol Date: 2017-08-16

4. Activation of RAS family members confers resistance to ROS1 targeting drugs.

Authors: Marilisa Cargnelutti; Simona Corso; Margherita Pergolizzi; Laurence Mévellec; Dara L Aisner; Rafal Dziadziuszko; Marileila Varella-Garcia; Paolo M Comoglio; Robert C Doebele; Jorge Vialard; Silvia Giordano
Journal: Oncotarget Date: 2015-03-10

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

1. Liquid biopsy: Potential and challenges.

Review 2. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

3. Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer.

4. Activation of RAS family members confers resistance to ROS1 targeting drugs.

Review 5. Platelet RNA signatures for the detection of cancer.

Review 6. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

Review 7. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.

Review 8. Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine.